Wolfgang Jacob

2.1k total citations · 1 hit paper
29 papers, 1.0k citations indexed

About

Wolfgang Jacob is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Wolfgang Jacob has authored 29 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 13 papers in Radiology, Nuclear Medicine and Imaging and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Wolfgang Jacob's work include HER2/EGFR in Cancer Research (11 papers), Monoclonal and Polyclonal Antibodies Research (10 papers) and Peptidase Inhibition and Analysis (4 papers). Wolfgang Jacob is often cited by papers focused on HER2/EGFR in Cancer Research (11 papers), Monoclonal and Polyclonal Antibodies Research (10 papers) and Peptidase Inhibition and Analysis (4 papers). Wolfgang Jacob collaborates with scholars based in Germany, United Kingdom and Switzerland. Wolfgang Jacob's co-authors include Maja Weisser, Carola H. Ries, Michael A. Cannarile, Anna-Maria Jegg, Dominik Rüttinger, Ian James, Max Hasmann, Maurizio Ceppi, Céline Adessi and Georgina Meneses‐Lorente and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Wolfgang Jacob

24 papers receiving 989 citations

Hit Papers

Colony-stimulating factor 1 receptor (CSF1R) inhibitors i... 2017 2026 2020 2023 2017 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy
    2017 747 citations Michael A. Cannarile, Maja Weisser et al. Journal for ImmunoTherapy of Cancer profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Wolfgang Jacob Germany 8 523 506 246 166 145 29 1.0k
Xuejin Ou China 15 415 0.8× 393 0.8× 204 0.8× 164 1.0× 347 2.4× 22 1.1k
Dan Branstetter United States 7 588 1.1× 354 0.7× 486 2.0× 81 0.5× 63 0.4× 9 1.1k
Candice C. Poon Canada 9 394 0.8× 459 0.9× 344 1.4× 113 0.7× 52 0.4× 14 1.2k
Gillian A. Kingsbury United States 12 194 0.4× 334 0.7× 163 0.7× 52 0.3× 66 0.5× 19 708
Anna-Maria Jegg Switzerland 4 397 0.8× 538 1.1× 205 0.8× 111 0.7× 18 0.1× 4 836
Shahrzad Jalali United States 17 406 0.8× 383 0.8× 199 0.8× 53 0.3× 82 0.6× 39 952
Lunxu Liu China 11 351 0.7× 286 0.6× 345 1.4× 261 1.6× 50 0.3× 46 953
Linda N. Liu United States 12 747 1.4× 672 1.3× 609 2.5× 274 1.7× 72 0.5× 20 1.4k
Renato G.S. Chirivi Italy 17 208 0.4× 321 0.6× 362 1.5× 75 0.5× 76 0.5× 28 791
Yonggao Mou China 17 265 0.5× 194 0.4× 294 1.2× 216 1.3× 81 0.6× 60 892

Countries citing papers authored by Wolfgang Jacob

Since Specialization
Citations

This map shows the geographic impact of Wolfgang Jacob's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wolfgang Jacob with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wolfgang Jacob more than expected).

Fields of papers citing papers by Wolfgang Jacob

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wolfgang Jacob. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wolfgang Jacob. The network helps show where Wolfgang Jacob may publish in the future.

Co-authorship network of co-authors of Wolfgang Jacob

This figure shows the co-authorship network connecting the top 25 collaborators of Wolfgang Jacob. A scholar is included among the top collaborators of Wolfgang Jacob based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wolfgang Jacob. Wolfgang Jacob is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
Jacob, Wolfgang, Ian James, Max Hasmann, & Maja Weisser. (2018). Clinical development of HER3-targeting monoclonal antibodies: Perils and progress. Cancer Treatment Reviews. 68. 111–123. 43 indexed citations
4.
Kim, Hye Sook, Ji‐Youn Han, Dong Hoon Shin, et al.. (2018). EGFR and HER3 signaling blockade in invasive mucinous lung adenocarcinoma harboring an NRG1 fusion. Lung Cancer. 124. 71–75. 23 indexed citations
5.
Moisan, Annie, Francesca Michielin, Wolfgang Jacob, et al.. (2018). Mechanistic Investigations of Diarrhea Toxicity Induced by Anti-HER2/3 Combination Therapy. Molecular Cancer Therapeutics. 17(7). 1464–1474. 18 indexed citations
6.
Bensch, Frederike, Laetitia E. Lamberts, Annelies Jorritsma‐Smit, et al.. (2017). 89Zr-Lumretuzumab PET Imaging before and during HER3 Antibody Lumretuzumab Treatment in Patients with Solid Tumors. Clinical Cancer Research. 23(20). 6128–6137. 57 indexed citations
7.
Meneses‐Lorente, Georgina, Christine McIntyre, Joy Hsu, et al.. (2017). Accelerating drug development by efficiently using emerging PK/PD data from an adaptable entry-into-human trial: example of lumretuzumab. Cancer Chemotherapy and Pharmacology. 79(6). 1239–1247. 3 indexed citations
8.
Collins, Denis M., Wolfgang Jacob, Juan Miguel Cejalvo, et al.. (2017). Direct estrogen receptor (ER) / HER family crosstalk mediating sensitivity to lumretuzumab and pertuzumab in ER+ breast cancer. PLoS ONE. 12(5). e0177331–e0177331. 39 indexed citations
9.
Han, Ji‐Youn, Kun Young Lim, Jin Young Kim, et al.. (2017). P3.02c-006 EGFR and HER3 Inhibition - A Novel Therapy for Invasive Mucinous Non-Small Cell Lung Cancer Harboring an NRG1 Fusion Gene. Journal of Thoracic Oncology. 12(1). S1274–S1275. 5 indexed citations
10.
Cannarile, Michael A., Maja Weisser, Wolfgang Jacob, et al.. (2017). Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy. Journal for ImmunoTherapy of Cancer. 5(1). 53–53. 747 indexed citations breakdown →
11.
12.
Bensch, Frederike, Laetitia E. Lamberts, Annelies Jorritsma‐Smit, et al.. (2016). 89Zr-lumretuzumab PET imaging before and during HER3 antibody lumretuzumab treatment of solid tumor patients.. Journal of Clinical Oncology. 34(15_suppl). 11555–11555. 1 indexed citations
13.
14.
Meulendijks, Didier, Martijn P. Lolkema, Emile E. Voest, et al.. (2013). A first-in-human trial of RG7116, a glycoengineered monoclonal antibody targeting HER3, in patients with advanced/metastatic tumors of epithelial cell origin expressing HER3 protein.. Journal of Clinical Oncology. 31(15_suppl). 2522–2522. 7 indexed citations
15.
Kayser, Klaus, et al.. (1977). Medical thesaurus. Medical Informatics. 2(1). 47–55. 1 indexed citations
16.
Jacob, Wolfgang. (1972). Documentation methods and retrieval purposes in a Pathological Institute.. PubMed. 7(2). 187–92. 2 indexed citations
17.
Jacob, Wolfgang, et al.. (1972). Zur Methodik der statistischen Sicherung epidemiologischer Aussagen in der Pathologie. 356(2). 127–139. 1 indexed citations
18.
Jacob, Wolfgang, et al.. (1972). Action of Epinephrine on Amino Acid Uptake into Rat Diaphragm <i>in vitro </i>and <i>in viv</i><i>o</i>. Pharmacology. 7(5-6). 327–348. 2 indexed citations
19.
Jacob, Wolfgang, et al.. (1971). Action of Epinephrine on the Distribution of Two Model Amino Acids in the Diabetic Rat. Pharmacology. 5(1). 9–22. 1 indexed citations
20.
Jacob, Wolfgang. (1955). Bronchospirometrie unter leichter Belastung. Lung. 113(2). 146–156. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Xuejin Ou Breakdown of academic impact, for papers by Dan Branstetter Breakdown of academic impact, for papers by Candice C. Poon Breakdown of academic impact, for papers by Gillian A. Kingsbury Breakdown of academic impact, for papers by Anna-Maria Jegg Breakdown of academic impact, for papers by Shahrzad Jalali Breakdown of academic impact, for papers by Lunxu Liu Breakdown of academic impact, for papers by Linda N. Liu Breakdown of academic impact, for papers by Renato G.S. Chirivi Breakdown of academic impact, for papers by Yonggao Mou
Rankless by CCL
2026